Transcatheter arterial chemoembolization (TACE) plays an important role in the treatment of unresectable liver cancer. We conducted this meta-analysis to compare the clinical safety and efficacy of conventional TACE (C-TACE) and drug-eluting beads (DEB)-TACE. A search for those procedures was performed using the PubMed, EMBASE, and Cochrane Library databases. A meta-analysis of patients who underwent C-TACE or DEB-TACE was conducted. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated. Of 334 studies, 30 were analyzed. The complete response rate, disease control rate, objective response rate, 3-year survival rate, and non-response rate were significantly higher in patients who underwent DEB-TACE than those in patients who underwent C-TACE. The 1-year survival rate, 2-year survival rate, 30-day mortality rate, complete response rate, disease control rate, complete necrosis rate, non-response rate, objective response rate, progressive disease rate, and recurrence did not differ significantly between patients who underwent C-TACE and patients who underwent DEB-TACE. Patients who undergo DEB-TACE might have a higher complete response rate, disease control rate, and 3-year survival rate than patients who undergo C-TACE. Safety did not differ significantly between C-TACE and DEB-TACE.
Introduction
Hepatocellular carcinoma (HCC) is the 6th most common malignant tumor, and it ranks 3rd in terms of cancer-related deaths, with an overall survival rate of 3-5% (1). Unfortunately, its incidence is still rising around the world (2) . Hepatitis viral infections and alcoholism are the dominant factors that trigger HCC. Diabetes, obesity, and metabolic disorders are also associated with HCC (3). Common treatments include resection, ablation, chemoembolization, radiotherapy, and chemotherapy (4) . The preferred approach, surgical resection can increase the 5-year survival rate to 60% (5) . However, most patients exhibit nonspecific clinical symptoms, so when the condition is ultimately diagnosed they are unable to undergo radical surgery (6) . Only 10-15% of patients with HCC are eligible for surgical resection. As a downstaging therapy, transcatheter arterial chemoembolization (TACE) has been widely used to treat unresectable HCC, and it can improve the overall survival of patients with HCC (7, 8) .
In TACE, a suspension consisting of a chemotherapy drug and lipiodol is delivered via a catheter to the hepatic artery branch of the diseased liver. The released chemotherapy drug then plays an antagonistic role. Drugeluting beads transcatheter arterial chemoembolization (DEB-TACE) has often been performed over the past decade. Its major differences compared to conventional TACE (C-TACE) are a higher adsorption capacity of the chemotherapy drug and a slower and more consistent release (9) . Considering the rapid metabolism of chemotherapy drugs in C-TACE, drug use should theoretically be better in DEB-TACE. However, its therapeutic efficacy and safety are debated. Therefore, this meta-analysis was performed.
Methods

Search strategy
A search of the PubMed, EMBASE, and the Cochrane Library databases was conducted. The last search was conducted on July 30, 2016. Search terms were as follows: "TACE," "DEB-TACE," and "hepatocellular carcinoma." The full text of each identified article was read, and irrelevant articles were discarded. If the same subjects were referenced across multiple articles or if an article included more subjects or provided more overall information than another article, then the article was selected for meta-analysis.
Eligibility criteria
Eligible studies were randomized controlled trials (RCTs) or prospective or retrospective cohort and casecontrol studies published prior to June 2016 that met the following inclusion criteria: i) directly compared C-TACE and DEB-TACE in patients with HCC; ii) reported at least one of the following data: response rate and survival rate; iii) reported the relative odds ratio (OR) and hazard ratio (HR) or provided data for their calculation; and iv) articles written in English.
Case reports and abstracts or studies with insufficient data were excluded. If multiple articles included the same subjects, only the most recent and complete article was analyzed. When information was incomplete, attempts were made to contact the corresponding authors for additional data.
Data extraction
Once the researchers agreed on the articles to include, a flow chat was created. The relevant information was as follows: first author, date of publication, country, study design, enrollment period, type of patients, groups, number of patients, number of procedures, previous TACE, locoregional treatment, Child-Pugh stage, Barcelona Clinic Liver Cancer Center (BCLC) stage, Okuda stage, ECOG performance status, and Milan tumor criteria.
Assessment of study quality
The quality of eligible RCTs and non-RCTs was respectively evaluated using the Cochrane Handbook for Systematic Reviews of Interventions and the Newcastle-Ottawa scale. The Cochrane Handbook for Systematic Reviews of Interventions consists of 6 items: adequacy of the generation of allocation sequence, allocation concealment, blinding, the presence of incomplete outcome data, selective outcomes, and other sources of bias. The Newcastle-Ottawa scale consists of 3 items including selection (4 points), comparability (2 points), and exposure (3 points).
Data analysis
Odds ratios (ORs) with 95% confidence intervals (CIs) were calculated to compare C-TACE and DEB-TACE, and only a random-effects model was used. All tests were two-tailed, and p values of less than 0.05 were statistically significant. The I 2 statistic and Chi-square test were used to evaluate heterogeneity. When I 2 > 50% or p < 0.10, heterogeneity was statistically significant. All statistical analyses were performed using Stata.
Results
Study selection and characteristics
As shown in Figure 1 , 334 studies were initially identified. After preliminary exclusion of abstracts or papers not fulfilling the search criteria, 46 potentially relevant articles were examined. Of these studies, 14 were excluded due to incomplete data. Two studies reported information on the same subjects, and two other studies were published by the same group with overlapping recruitment periods. Ultimately, 30 studies, including 5 RCTs and 25 observational studies, involving 3,195 patients (1,444 treated with DEB-TACE and 1746 with C-TACE) were included in the meta-analysis.
Eight studies were conducted in Italy, 4 studies were conducted in Germany, 4 in the US, 3 in South Korea, 3 in Spain, 2 in Australia, 2 in the UK, 1 in Belgium, 1 in Taiwan, and 1 in Saudi Arabia. Baseline data and the characteristics of studies and patients are shown in Table 1 . Five studies were of high quality, one study was of moderate quality, and one study was of poor quality.
Comparison of the complete response rate
Two studies involving 167 subjects reported the complete response rate. The complete response rate was
Comparison of the survival rate
Fourteen studies involving 1,645 patients estimated the overall survival (OS) and compared the two groups using log-rank tests (13,16,17,19,21,23,24,26,28,31 ,34,35,38) . As described in Table 2 , the two groups had a similar 1-year survival rate (SR) that tended to be higher, albeit not significantly so, in patients who underwent DEB-TACE (OR 1.51, 95% CI 0.48-1.21, p = 0.08) ( Figure 3 ). With treatment, survival was prolonged and the OR tended to decrease, albeit not significantly so, thus indicating better long-term outcomes in patients who underwent DEB-TACE (2year SR: OR 1.32, 95% CI 0.74-2.36, p = 0.34; 3-year SR: OR 1.92, 95% CI = 1.00-3.68, p = 0.049). The meta-analysis of plotted HRs revealed no significant differences in the 1-year survival rate and 2-year survival rate. The 3-year survival rate was significantly higher in patients who underwent DEB-TACE than that in patients who underwent C-TACE (OR = 1.92, 95% CI = 1.00-3.67, p = 0.049), and statistical heterogeneity was evident (p = 0.043, I 2 = 51.7%).
Discussion
This meta-analysis included a large number of studies on the efficacy and safety of TACE and DEB-TACE. A total of 30 studies (5 RCTs and 25 observational studies) involving 2,920 patients were analyzed. The DEBs, from 150 to 650 nm in size, were loaded with doxorubicin in all of the studies. The C-TACE arms widely differed with regard to the drugs used ( Table 1 ). The current study indicated that patients who underwent DEB-TACE might have a higher complete response rate and disease control rate than patients who underwent C-TACE. In addition, meta-analysis indicated that the 1-year survival rate and 2-year survival rate did not differ significantly between significantly higher in patients who underwent DEB-TACE than that in patients who underwent C-TACE (OR = 3.59, 95% CI = 1.48-8.72, p = 0.0048) without any significant heterogeneity (p = 0.91, I 2 = 0%).
Comparison of the disease control rate
Nine studies involving 909 subjects reported the disease control rate (19, 21, 25, 26, 30, 32, 35, 36, 38) . Of those studies, 2 were published by the same group. Ultimately, eight studies involving 869 patients were analyzed. The disease control rate was significantly higher in patients who underwent DEB-TACE than that in patients who underwent C-TACE (OR = 2.17, 95% CI = 1.22-3.87, p = 0.0082), and statistical heterogeneity was evident (p = 0.08, I 2 = 44.8%).
Comparison of the objective response rate
The overall response rate (ORR) was reported in 13 studies (12, 17, 19, 21, 25, 26, (30) (31) (32) 34, 35, 36, 38) . Due to the high heterogeneity found among the included studies ( χ 2 = 6.67, d.f. = 10, I 2 = 71%; p = 0.011), the DerSimonian and Laird test for the random-effects models was used. The objective response rate was significantly higher in patients who underwent DEB-TACE than that in patients who underwent C-TACE (OR = 2.05, 95% CI = 1.17-3.55, p = 0.011), and statistical heterogeneity was evident (p = 0.0001, I 2 = 71%). Subgroup analyses of RCTs and observational studies confirmed the non-significant OR in favor of DEB-TACE (OR = 1.27, 95% CI = 0.78-2.07 and OR = 2.40, 95% CI = 1.17-4.90, respectively) and detected, as expected, a high heterogeneity among the observational studies ( Figure 2 ). The high heterogeneity may be caused by response assessment, namely, the timing of the response assessment, the response criteria, and the study design and quality. (10) Arabi 2015 (11) Bloom 2012 (12) Burrell 2014 (13) Castelli 2013 (14) Cuomo 2011 (15) Dhanasekaran 2010 (16) Facciorusso 2016 (17) Farris 2010 (18) Ferrer Puchol 2011 (19) Frenette 2012 (20) Golfieri 2014 (21) Gorodetski 2015 (22) Kloeckner 2015 ( 104  145  13  13  25  47  148  127  88  89  95  38  174  76  38  81  108  93  105  53  14  16  30  30  67  63  8   8  16  22  52  20  70  35  34  33  69  60  20   20  108  93  22  22  19  15 Study (17) , perhaps because the current meta-analysis analyzed more studies. However, longterm follow-up needs to be conducted and more standard randomized studies need to be assembled to assess the survival benefit of DEB-TACE. The complete response rate, disease control rate, full necrosis rate, non-response rate, objective response rate, progressive disease rate, and recurrence did not differ significantly between patients who underwent C-TACE and patients who underwent DEB-TACE. Safety did not differ significantly between C-TACE and DEB-TACE. Many clinical research studies suggest that tumor eradication cannot readily be achieved with TACE and that HCC can only be controlled by palliative treatment. Therefore, a low adverse reaction rate and a high tumor response rate in DEB-TACE therapy will be advantageous to patients needing to undergo radical surgery in the short term. Because this population of patients is in the early stage of disease, DEB-TACE can be an efficient and safe way to control the tumor, downregulate the tumor stage, and protect liver function to the greatest extent. In theory, therefore, DEB-TACE will lay a better foundation for radical surgery and possibly prolong long-term survival.
This meta-analysis provides relatively comprehensive evidence of the benefits of DEB-TACE compared to C-TACE for the treatment of primary liver cancer, but there are still some limitations to this study. First, the evaluation criteria for tumor response in the included literature were not entirely consistent, and mRECIST and EASL standards assess tumor response differently, which may lead to different interpretations. Second, treatment with conventional technology has matured, but many of the RCT designs lacked conventional standardization of evaluation metrics, and this was especially true for C-TACE involving conventional technology and chemotherapy drugs for embolism.
In conclusion, this meta-analysis has shown that patients who underwent DEB-TACE might have a higher complete response rate, disease control rate, and 3-year survival rate than patients who underwent C-TACE. Safety did not differ significant between C-TACE and DEB-TACE. Therefore, DEB-TACE may be a better choice for patients with primary HCC than liver transplantation, liver resection, or partial ablation in the short term.
